Quantinno Capital Management LP Acquires 120,120 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Quantinno Capital Management LP lifted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 33.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 481,833 shares of the company's stock after purchasing an additional 120,120 shares during the quarter. Quantinno Capital Management LP's holdings in Takeda Pharmaceutical were worth $6,379,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TAK. Park Avenue Securities LLC increased its holdings in Takeda Pharmaceutical by 28.3% in the 4th quarter. Park Avenue Securities LLC now owns 27,651 shares of the company's stock valued at $366,000 after purchasing an additional 6,094 shares in the last quarter. Aaron Wealth Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 7.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock worth $331,000 after purchasing an additional 1,670 shares during the last quarter. Ballentine Partners LLC lifted its holdings in Takeda Pharmaceutical by 24.3% in the fourth quarter. Ballentine Partners LLC now owns 38,662 shares of the company's stock worth $512,000 after acquiring an additional 7,568 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company's stock worth $2,787,000 after acquiring an additional 155,795 shares during the last quarter. Finally, DGS Capital Management LLC bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $148,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.1%

Shares of NYSE:TAK traded up $0.01 during trading on Tuesday, reaching $14.24. 1,681,900 shares of the company traded hands, compared to its average volume of 1,920,428. The firm has a fifty day simple moving average of $14.75 and a 200 day simple moving average of $14.00. The firm has a market cap of $45.31 billion, a P/E ratio of 35.60, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.